U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Fintel reports that on January 30, 2025, Wells Fargo downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $428, representing a +0.03% change from its previous close.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.